Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing treatments and diagnostics for central nervous system disorders, including Alzheimer’s disease and Tuberous Sclerosis Complex (TSC)-related epilepsy. Its core assets include simufilam, an oral small-molecule drug targeting the brain protein filamin A, and SavaDx, a blood-based diagnostic assay. The company leverages proprietary science, patent-protected technology, and collaborations to advance novel therapies for neurodegenerative diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.